Fleurish Cannabis is a Canadian company licensed to produce cannabis for medical purposes. Originally founded in 2013 under the name Farmacopia by Renée Ellison, the company has always maintained a focus on compliance, quality, and consistency in its operations. In 2017, the company adopted the name Fleurish, inspired by the word “flower,” in reference to the female cannabis plant and the natural growth process that defines its cultivation approach.
Located in Oxford Station, Ontario, Fleurish operates from an eight-acre agricultural property equipped with greenhouse facilities. These controlled environments allow for regulated cultivation methods, aligned with federal standards. Fleurish is authorized under the Cannabis Act and associated regulations to produce and distribute cannabis for individuals who have received proper medical authorization. All processes—ranging from propagation and harvesting to drying and packaging—are conducted with precision, adhering to the strict requirements set by Health Canada.
Fleurish offers a range of cannabis products for medical use, including dried flower, pre-rolls, and vaporizer cartridges. Each product undergoes standardized processes to ensure consistent characteristics and is packaged in a manner that supports product stability and freshness. The packaging also complies with Canadian requirements, including child-resistant features and informational labelling as mandated by law.
The company’s philosophy integrates a patient-centered production model, aiming to meet a variety of medical cannabis needs. While not targeting any specific demographic in its product formulations, Fleurish has taken into account feedback from diverse patient populations, with a particular awareness of women’s perspectives—an approach that echoes the values and vision of its founder.
Fleurish is an approved supplier through Teedy, a regulated medical cannabis platform that facilitates legal access for individuals holding a valid medical authorization. Through this platform, registered patients can securely order medical cannabis products for delivery. All shipments are processed through channels that comply with federal privacy and security standards, ensuring discreet and timely delivery across Quebec and other Canadian provinces.
In 2022, Fleurish introduced a sub-brand called Growtown, a project created to support Canada’s community of small-scale licensed producers. Through Growtown, these authorized producers gain visibility and an opportunity to distribute their products under an established and compliant brand. This initiative aligns with Fleurish’s commitment to collaborative efforts within the regulated cannabis sector and highlights the importance of responsible representation for smaller producers.
Fleurish’s continued involvement in the Canadian medical cannabis landscape reflects its commitment to lawful production and access. The company operates exclusively within the limits of federal law, and its products are available solely to individuals who have obtained the appropriate medical documentation in accordance with Health Canada’s guidelines.
Medical cannabis from Fleurish is not available for general consumer use and may only be accessed through verified medical channels. The company does not engage in promotional activities that contravene the Cannabis Act, including inducements, testimonials, endorsements, or price-based promotions. All communication surrounding the company’s offerings is intended to inform and provide clarity within the context of Canada’s legal medical cannabis framework.
